Orion’s net sales swelled, the result on a strong level – in the background of Nubeqa’s ferocious tone

Pharmaceutical company Orion announced its annual financial statements on Tuesday.

The company’s profit figures and turnover were already known by the company, as the company reported in January with a positive earnings warning in January.

The company’s operating profit in October -December was EUR 92.7 million, compared with EUR 92.9 million during the year -long comparison period.

Net sales increased to EUR 434.4 million from EUR 321.1 million.

The result of the comparison period was stronger than usual as it was accompanied by a € 30.7 million installment of the Orion Pension Foundation’s insurance portfolio. When the positive installment and milestone fees are ignored, the company’s operating profit increased by more than 30 percent last year.

Database Factsetin With analysts listed, earnings forecasts corresponded to the figures reported in January: net sales were estimated at EUR 434 million and the result is EUR 93 million.

The company’s share earnings reached EUR 0.52 per share. The analysts expected it to grow to EUR 0.53 for a quarter of EUR 0.53.

The company made an operating profit of EUR 416.6 million throughout the year with a turnover of EUR 1,542.4 million. In 2023, operating profit was EUR 274.9 million.

The Board of Directors of the Company proposes a dividend of EUR 1.64 for the last financial year. The average forecast was EUR 1.73 per share, while last year it was paid EUR 1.62 per share.

The company’s sales were accelerated throughout the year, especially for the treatment of prostate cancer, and the company receives royalties. The sale of the drug has developed strongly in recent years, and the partner company Bayer has repeatedly raised estimates of its sales figures.

In the guidelines for growth of revenue

The company’s turnover is estimated to be EUR 1,550-1650 million in 2025. The operating profit is estimated to be EUR 350-450 million.

In 2024, Orion recorded two essential milestones of EUR 130 million. The 2025 view estimate does not include essential milestones or one -off items.

View estimates assume that Nubaqa rats and product sales recorded by Orion will increase clearly in 2025. However, it is difficult to assess the exact level of sales of a strongly growing product and royalties throughout the year.

“Four of our five profit units increased their turnover in 2024. We are very pleased with our expectations for faster growth and our partner Bayer achievements in the market. Market sales in the Nubeqa calendar year exceeded a billion euros in September 2024, which was a great borderline for both companies, ”says the company’s CEO Liisa Hurme in the profit file.

“Net sales without significant milestones increased by more than 20 percent from the previous year. Operating profit increased by more than 30 percent, ignoring significant milestones and a positive installment of the Insurance Stock of the Orion Pension Foundation during the comparison period. Thanks to a strong year, we achieved our ambitious goal of our 2019 reached EUR 1.5 billion in 2019 by the end of 2025. ”

According to Hurme, the company’s Easyhaler Product Portfolio continued throughout the year and spanned the Branded Products unit growth. The Generics and Consumer Health Business Unit improved its development throughout the year. The Animal Health result unit grew strongly, although much of the growth will be explained by the return to normal after 2023.

“Fermion’s net sales were at the previous year’s level, which is also a good performance, taking into account that the demand for active substances in Orion’s own indigenous drugs at the same time has increased.”

“We also increased investments in research and development, sales and marketing as planned. These determined investments are aimed at growth in Orion in both short and long periods of time. ”